A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06428409

Title field or adapter rule

{'original_value': 'A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:21.367075+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:18:26.854673+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06428409"

protocolSection.identificationModule.officialTitle

"A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Colorectal Cancer (protocolSection.conditionsModule.conditions)
• Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Biliary Tract Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Sacituzumab tirumotecan', 'Sacituzumab tirumotecan + Chemotherapy', 'Sacituzumab tirumotecan + Cisplatin + Pembrolizumab'], 'description': 'Given by IV infusion.', 'name': 'Sacituzumab tirumotecan', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Sacituzumab tirumotecan + Chemotherapy'], 'description': '5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks.', 'name': 'Fluorouracil (5-FU)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Sacituzumab tirumotecan + Chemotherapy'], 'description': 'LV or levoleucovorin is administered by IV infusion every 2 weeks.', 'name': 'Leucovorin (LV) or levoleucovorin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Sacituzumab tirumotecan', 'Sacituzumab tirumotecan + Chemotherapy', 'Sacituzumab tirumotecan + Cisplatin + Pembrolizumab'], 'description': 'Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 \\[H1\\] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.', 'name': 'Rescue medication', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Sacituzumab tirumotecan', 'Sacituzumab tirumotecan + Chemotherapy', 'Sacituzumab tirumotecan + Cisplatin + Pembrolizumab'], 'description': 'Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as supportive care for Ocular Surface Toxicity.', 'name': 'Supportive care measures', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Sacituzumab tirumotecan + Cisplatin + Pembrolizumab'], 'description': 'Given by IV infusion.', 'name': 'Cisplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Sacituzumab tirumotecan + Cisplatin + Pembrolizumab'], 'description': 'Given by IV infusion.', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Fluorouracil (5-FU) (protocolSection.armsInterventionsModule.interventions[].name)
• Leucovorin (LV) or levoleucovorin (protocolSection.armsInterventionsModule.interventions[].name)
• Rescue medication (protocolSection.armsInterventionsModule.interventions[].name)
• Supportive care measures (protocolSection.armsInterventionsModule.interventions[].name)
• Cisplatin (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.